xBiologix, Inc

Making Oncology Work®

    __________________________________________________________________________________

xBiologix is a pre-seed start-up developing color biopsies that clinicians can use to screen their patient's tumor against available drug targets. With color biopsies, clinicians can prescribe the right drugs for each patient immediately after the tumor is removed in surgery, but only if the drugs' targets are present and arrayed appropriately in the biopsy. Today, more than 65% of patients are diagnosed with solid tumors that do not respond to treatment. Color biopsies that screen for the full range of available therapies heralds the turning point in the war on cancer.

xBiologix uses its synthetic biology, platform technology to make reagents that drive the number of colors in a biopsy upward to 30+ colors, a major advantage over standard monochrome (immunohistochemistry based) biopsies which lack richly informative spectral and spatial resolution. And, by using instruments that clinical pathology labs often already own, xBiologix looks to close the yawning gap between prognosis and survival by enabling affordable, informed and timely treatment decisions in clinical settings.

xBiologix is currently serving three small drug developers, our alpha customers, helping them take their immunotherapy and cell treatments through clinical trial. Based on these engagements and interviews with prospective customers, we know that 100% of the target CxOs decide for us because (1) screening for patients who respond to their therapies on or about clinical trials significantly improved trial performance, and (2) screening newly resected tumors gives participating drug companies access to otherwise unavailable personalized, targeted treatment.

xBiologix expects to see potential exits as it grows to 30 customers in the 18-24 months following the close of the current open $1.5M raise— with $600K collected to date. Present margin is projected to produce $10M in profit on $16M in revenue in that time.

Going forward, either strategic or technology exists are possible in the 3-to-5-year timeframe. A likely strategic exit would involve a merger with one of many spatial biology platform companies in the $2B spatial biology market (TAM/2029); strategic exits currently run in the $50-150M range. A comparable technology exit occurred last year, closed with the purchase of a small technology company for $2.4B.